Contents
Market Overview
The Czech Republic remains one of Europe’s most liberal and progressive medical cannabis markets, underpinned by a pragmatic approach to drug policy and a strong domestic cultivation base.
The estimated medical cannabis market size for 2025 is over €3.5 million, with projections indicating growth to over €XXX million by 2029 (Prohibition Partners Market Sizing Forecasts, 2025–2029).
The country first established its medical cannabis framework in 2013, allowing patients with specific conditions to access treatment via prescription. While smaller in scale compared to major markets such as Germany or the UK, Czechia has recorded steady year-on-year growth in patient numbers and prescription volumes.
A significant policy milestone occurred in April 2025, when general practitioners (GPs) were authorised to prescribe medical cannabis for chronic pain, marking a pivotal step toward expanding access and reducing specialist bottlenecks.
The Czech Republic’s cultivation sector has also matured rapidly. Following the 2022 amendment to the Addictive Substances Act, which eliminated state tendering for domestic cultivation, companies can now apply for individual licences. This has led to the emergence of a competitive domestic industry, supported by several EU-GMP certified producers and growing export activity.
In 2024, the Czech Republic exported over 1,300 kilograms of medical cannabis to Germany, solidifying its status as an emerging European exporter.
Regulatory Framework
The Czech Republic first legalised medical cannabis through Act No. 50/2013 Coll. on Pharmaceuticals and Addictive Substances, establishing a foundation for cultivation, distribution, and prescription.
Regulatory oversight is shared between:
- The Ministry of Health, responsible for defining eligible medical conditions and overseeing framework amendments.
- The State Institute for Drug Control (SÚKL), responsible for issuing licences for cultivation, import, distribution, and product handling of addictive substances.
The 2022 amendment to the Addictive Substances Act removed the state tender system, enabling private companies to obtain direct cultivation licences. This reform has:
- Increased the number of suppliers and available product varieties.
- Enabled the development of an export market.
- Driven price reductions for patients through competition.
In August 2022, Decree No. 235/2022 on the cultivation and processing of cannabis for medical use was enacted, setting out detailed requirements for cultivation practices, security, storage, processing, and record-keeping.
Compared to other EU markets, the Czech Republic has shown a proactive regulatory stance, frequently updating decrees to improve access and facilitate commercial growth.d by the European Medicines Agency, such as Sativex, which remains available under a restricted prescription pathway.
Patient Access
Who Can Prescribe?
As of April 2025, both general practitioners and medical specialists can prescribe medical cannabis for chronic pain. For all other conditions, prescriptions must be issued by a relevant specialist, including those in:
- Clinical or Radiation Oncology
- Neurology
- Ophthalmology
- Psychiatry
- Palliative Medicine
- Pain Management
- Rheumatology
- Dermatovenerology
- Orthopaedics
- Infectious Diseases
- Internal Medicine
- Geriatrics
Treatable Pathologies:
- Chronic intractable pain (oncological, musculoskeletal, connective tissue diseases, neuropathic, glaucoma-related)
- Spasticity associated with multiple sclerosis or spinal cord injury
- Nausea, vomiting, appetite stimulation (cancer or HIV-related)
- Gilles de la Tourette syndrome
- Superficial treatment of dermatoses and mucosal lesions
➡️ Specialists must prescribe within their area of expertise (e.g., ophthalmologists for glaucoma).
Reimbursement:
Public health insurers reimburse 90% of treatment costs for up to 30 grams per month. Any additional quantities are paid out-of-pocket by the patient.
Patient Trends:
- Annual patient growth rate: 10–15%.
- 2024: 318 kg dispensed.
- H1 2025: 170 kg dispensed, with projections exceeding 350 kg by year-end.
- Market remains flower-dominant (90%), though extracts have grown from 8% (2022) to 14% by end-2024.
Products & Prices
The Czech Republic offers one of the most diverse medical cannabis product catalogues in Central Europe.
Pricing:
- Flower: €5–€8 per gram before VAT (capped at CZK 143.75/g (€5.7) for domestic products).
- Extracts: Price cap of CZK 1,006.25 (€40) per gram before VAT.
- Public insurers cover 90% of the cost for up to 30 grams/month.
Product Portfolio:
- Flower: 65 registered products.
- 41 high-THC
- 9 balanced
- 15 CBD-dominant
- Extracts: 5 approved products (THC, CBD, and balanced).
Suppliers and Manufacturers:
Imports from Denmark, Portugal, and Lesotho (typically via Germany).
Aurora (Canada) – leading importer and brand portfolio.
Lagom Pharmatech, SensiQure, Zenplanto, Motagon – domestic EU-GMP cultivators expanding export capacity.
Imports & Exports
The Czech Republic remains partially import-dependent, though its export capacity is growing rapidly.
Key Export Developments:
- 2024: First commercial exports to Germany, totalling 1,300 kg.
- Exporters:
- SensiQure (via Phytopemp & Nimbus Health)
- Lagom Pharmatech
- Czech Medical Herbs (via Drapalin Pharmaceuticals)
Exports are expected to grow throughout 2025 as Czech cultivators secure additional EU-GMP certification and expand relationships with German distributors.able climate for controlled cultivation has positioned Denmark as a key global supplier of pharmaceutical-grade cannabis.
Outlook
The Czech Republic’s medical cannabis market is entering a phase of accelerated growth, supported by regulatory flexibility, expanded prescriber eligibility, and an emerging export ecosystem.
While domestic demand remains moderate, falling prices, expanding product diversity, and insurer reimbursement continue to drive patient adoption. With rising exports to Germany and a competitive domestic cultivation sector, the Czech Republic is positioning itself as a regional hub for high-quality, compliant medical cannabis.
